Green iron start-up Element Zero has lost its latest bid to set aside search orders in a case by Fortescue alleging former employees misappropriated its process for carbon dioxide-free iron.
Otsuka Pharmaceuticals is challenging a decision revoking its patent for an injectable version of antipsychotic drug Abilify.
Generic drug maker Sun Pharma has succeeded in invalidating Otsuka Pharmaceutical’s patent for an injectable, controlled release form of the Japanese drug maker’s top-selling antipsychotic Abilify.
Pharmaceutical giant Novartis is challenging the loss of its case against Sydney-based generics company Pharmacor over a patent for heart medication Entresto.
Radio manufacturer Hytera wants the High Court to hear its appeal of a finding that it misappropriated Motorola’s source code in a case of “substantial industrial theft”.
An appeals court has rejected Chinese radio manufacturer Hytera’s challenge to a finding it misappropriated the source code of US mobile phone giant Motorola.
Indian drug maker Cipla has lost a challenge to the extension of Novo Nordisk’s patent for Victoza, with a judge rejecting an argument that extensions can be granted only for active ingredients.
Element Zero has denied claims that three former Fortescue employees, including one executive, misused confidential information and developed a green iron process on the company dime.
Swiss pharmaceutical giant Novartis has lost its patent infringement case against Sydney-based generics company Pharmacor over a top-selling heart medication.
Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.